- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Alvotech to Manufacture Prestige's Biosimilars
Iceland-based Alvotech and Singapore-based Prestige Biopharma have entered a contract manufacturing partnership for Prestige’s biosimilars.
Iceland-based Alvotech and Singapore-based Prestige Biopharma have entered a contract manufacturing partnership for Prestige’s biosimilars.
Under the partnership, Alvotech will be responsible for commercial production at its new Reykjavik facility, where it will scale up and perform process validation.
Mark Levick, Alvotech’s chief executive officer, said in a statement that the partnership “marks an important milestone for our company as we work towards expanding our contract manufacturing business. We are pleased to be trusted with the responsibility of delivering high quality manufacturing services to Prestige Biopharma and look forward to further collaboration in the future. We pride ourselves on delivering highest quality commercial production from one of the best biopharma facilities in the world.”
The deal is the latest in a string of agreements related to biosimilars for Prestige, which in July entered into an exclusive agreement with Pharmapark LLC to supply and commercialize Prestige’s trastuzumab biosimilar, HD201, in Russia.
The Pharmapark deal came on the heels of an agreement with Mundipharma to license and supply the same biosimilar in parts of Europe.
In 2018, Prestige announced entered into a licensing agreement with Cipla Limited to distribute and market the biosimilar trastuzumab in some emerging markets, and even earlier, Prestige inked a deal with Alvogen to commercialize the biosimilar in Central and Eastern Europe.
In May of this year, the European Medicines Agency accepted for review a Marketing Authorization Application for HD201, and the company is also developing biosimilars referencing bevacizumab, adalimumab, denosumab, aflibercept, eculizumab, and ipilimumab.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
